Gold nanoparticles to improve HIV drug delivery.

BACKGROUND Antiretroviral therapy (ART) has improved lifespan and quality of life of patients infected with the HIV-1. However, ART has several potential limitations, including the development of drug resistance and suboptimal penetration to selected anatomic compartments. Improving the delivery of antiretroviral molecules could overcome several of the limitations of current ART. RESULTS & CONCLUSION Two to ten nanometer diameter inorganic gold crystals serve as a base scaffold to combine molecules with an array of properties in its surface. We show entry into different cell types, antiviral activity of an HIV integrase inhibitor conjugated in a gold nanoparticle and penetration into the brain in vivo without toxicity. Herein, gold nanoparticles prove to be a promising tool to use in HIV therapy.

[1]  K. Pettigrew,et al.  Regional cerebrovascular permeability to [14C]sucrose after osmotic opening of the blood-brain barrier , 1978, Brain Research.

[2]  R. Lanford,et al.  Signal-mediated nuclear transport in simian virus 40-transformed cells is regulated by large tumor antigen. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[3]  H. von Briesen,et al.  Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitro , 1996, Antimicrobial agents and chemotherapy.

[4]  R. Chaisson,et al.  Highly Active Antiretroviral Therapy in a Large Urban Clinic: Risk Factors for Virologic Failure and Adverse Drug Reactions , 1999, Annals of Internal Medicine.

[5]  Yanli Liu,et al.  Cellular trajectories of peptide-modified gold particle complexes: comparison of nuclear localization signals and peptide transduction domains. , 2004, Bioconjugate chemistry.

[6]  Jesus M de la Fuente,et al.  Tat peptide as an efficient molecule to translocate gold nanoparticles into the cell nucleus. , 2005, Bioconjugate chemistry.

[7]  Leon Hirsch,et al.  Gold nanoshell bioconjugates for molecular imaging in living cells. , 2005, Optics letters.

[8]  Chad A. Mirkin,et al.  Oligonucleotide-Modified Gold Nanoparticles for Intracellular Gene Regulation , 2006, Science.

[9]  Mansoor M. Amiji,et al.  Intracellular Delivery of Saquinavir in Biodegradable Polymeric Nanoparticles for HIV/AIDS , 2006, Pharmaceutical Research.

[10]  Chad A Mirkin,et al.  Gold nanoparticle probes for the detection of nucleic acid targets. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[11]  Arezou A Ghazani,et al.  Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. , 2006, Nano letters.

[12]  Drug targeting to the brain. , 2007, Annual review of pharmacology and toxicology.

[13]  E. Zubarev,et al.  Paclitaxel-functionalized gold nanoparticles. , 2007, Journal of the American Chemical Society.

[14]  K. Overton,et al.  Cellular uptake of gold nanoparticles passivated with BSA-SV40 large T antigen conjugates. , 2007, Analytical chemistry.

[15]  L. Zhang,et al.  Nanoparticles in Medicine: Therapeutic Applications and Developments , 2008, Clinical pharmacology and therapeutics.

[16]  Keishiro Tomoda,et al.  Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size. , 2008, Colloids and surfaces. B, Biointerfaces.

[17]  K. Landfester,et al.  The First Step into the Brain: Uptake of NIO‐PBCA Nanoparticles by Endothelial Cells in vitro and in vivo, and Direct Evidence for their Blood–Brain Barrier Permeation , 2008, ChemMedChem.

[18]  Christian Melander,et al.  Inhibition of HIV fusion with multivalent gold nanoparticles. , 2008, Journal of the American Chemical Society.

[19]  Petra Krystek,et al.  Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. , 2008, Biomaterials.

[20]  X. Wu,et al.  Solid Lipid Nanoparticles Enhance the Delivery of the HIV Protease Inhibitor, Atazanavir, by a Human Brain Endothelial Cell Line , 2008, Pharmaceutical Research.

[21]  C. Katlama,et al.  High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  A. Gerdon,et al.  Unexpected toxicity of monolayer protected gold clusters eliminated by PEG-thiol place exchange reactions. , 2010, Chemical research in toxicology.

[23]  S. Penadés,et al.  Gold nanoparticles capped with sulfate-ended ligands as anti-HIV agents. , 2010, Bioorganic & medicinal chemistry letters.

[24]  H. Gendelman,et al.  Nanoformulated Antiretroviral Drug Combinations Extend Drug Release and Antiretroviral Responses in HIV-1-Infected Macrophages: Implications for NeuroAIDS Therapeutics , 2010, Journal of Neuroimmune Pharmacology.

[25]  Lawrence Tamarkin,et al.  Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine , 2010, Clinical Cancer Research.

[26]  Keith E Maier,et al.  Identification of antibiotics using small molecule variable ligand display on gold nanoparticles. , 2010, Chemical communications.

[27]  D. Cliffel,et al.  Short-chain PEG mixed monolayer protected gold clusters increase clearance and red blood cell counts. , 2011, ACS nano.

[28]  Sozanne R. Solmaz,et al.  Molecular Architecture of the Transport Channel of the Nuclear Pore Complex , 2011, Cell.

[29]  Kenneth A. Dawson,et al.  Role of cell cycle on the cellular uptake and dilution of nanoparticles in a cell population. , 2011, Nature nanotechnology.

[30]  Marianne Frieri,et al.  Immune Response to Nanomaterials: Implications for Medicine and Literature Review , 2013, Current Allergy and Asthma Reports.

[31]  K. Hynynen,et al.  Enhanced delivery of gold nanoparticles with therapeutic potential into the brain using MRI-guided focused ultrasound. , 2012, Nanomedicine : nanotechnology, biology, and medicine.

[32]  Jinwoo Cheon,et al.  A facile approach for the delivery of inorganic nanoparticles into the brain by passing through the blood-brain barrier (BBB). , 2012, Chemical communications.

[33]  W. Law,et al.  Anti-HIV-1 nanotherapeutics: promises and challenges for the future , 2012, International journal of nanomedicine.

[34]  B. Ances,et al.  HIV-associated neurocognitive disorder. , 2013, The Lancet. Infectious diseases.

[35]  D. Cliffel,et al.  In vivo toxicity, biodistribution, and clearance of glutathione-coated gold nanoparticles. , 2013, Nanomedicine : nanotechnology, biology, and medicine.

[36]  K. Landfester,et al.  Complex encounters: nanoparticles in whole blood and their uptake into different types of white blood cells. , 2013, Nanomedicine.

[37]  C. Destache,et al.  Polymeric nanoparticles containing combination antiretroviral drugs for HIV type 1 treatment. , 2013, AIDS research and human retroviruses.

[38]  Huan‐Tsung Chang,et al.  Highly efficient inhibition of human immunodeficiency virus type 1 reverse transcriptase by aptamers functionalized gold nanoparticles. , 2013, Nanoscale.

[39]  R. Shoemaker,et al.  Nanoscale structure-activity relationships, mode of action, and biocompatibility of gold nanoparticle antibiotics. , 2014, Journal of the American Chemical Society.

[40]  M. Churchill,et al.  Is the central nervous system a reservoir of HIV-1? , 2014, Current opinion in HIV and AIDS.